Clinical Trial

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Study acronym: CAMILLA
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. The investigators believe that modulating the tumor microenvironment with biologic agents like cabozantinib will have synergistic effect when combined with checkpoint-based immunotherapeutics like durvalumab in this patient population. This is a phase I/II, open label, multi-cohort trial looking at safety, tolerability and efficacy endpoints.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2018-05-25; most recent amendment 2026-01-16.
Status change: Active, Not Recruiting → Recruiting 2025-01-10
Status change: Recruiting → Active, Not Recruiting 2023-07-11
Status change: Not Yet Recruiting → Recruiting 2018-09-17
Trial Details
NCT Number NCT03539822
Lead Sponsor Anwaar Saeed
Collaborators: AstraZeneca, Exelixis
Conditions Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
Enrollment 117 participants
Start Date 2018-10-22
Primary Completion 2028-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-21